Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 29, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Study: Afirma Genomic Test Can Reduce Unnecessary Fine Needle Aspiration Biopsies in Thyroid Cancer

 

A clinical utility study claimed use of the Afirma Gene Expression Classifier, developed by Veracyte Inc., can significantly reduce unnecessary surgeries in thyroid cancer diagnoses. The study was published in Cancer Cytopathology.

The Afirma Gene Expression Classifier is a 142-gene molecular test that identifies benign thyroid nodules among those deemed indeterminate by cytopathology. An additional 25 genes are used to differentiate uncommon neoplasm subtypes.



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter